In particular, bevacizumab inhibits the VEGF/VEGF receptor signaling pathway, blocking tumor angiogenesis (20, 23) decreasing microvessel density but inducing HIF-1 gene expression (24), which is a fleeting molecular balance that stimulates VEGF activity. Here, VEGFA is linked to neoplasm.